NCT02116257View on ClinicalTrials.gov

The Opioid-sparing Effect and Reduced PONV Using Propacetamol in PCA Among Patients With High Risk of PONV

NACompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
PONVPropacetamol
Interventions
DRUG

Propacetamol

total 4g of Propacetamol added to patient's PCA regimen

DRUG

PCA regimen

Trial Locations (1)

120-752

Severance Hospital, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT02116257 - The Opioid-sparing Effect and Reduced PONV Using Propacetamol in PCA Among Patients With High Risk of PONV | Biotech Hunter | Biotech Hunter